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Review Article
Prevalence of Telomerase Activity in Human Cancer
Chi-Hau Chen, Ruey-Jien Chen*
Telomerase activity has been measured in a wide variety of cancerous and non-cancerous tissue types, and
the vast majority of clinical studies have shown a direct correlation between it and the presence of cancer-
ous cells. Telomerase plays a key role in cellular immortality and tumorigenesis. Telomerase is activated in
80–90% of human carcinomas, but not in normal somatic cells, therefore, its detection holds promise as
a diagnostic marker for cancer. Measurable levels of telomerase have been detected in malignant cells from
various samples: tissue from gestational trophoblastic neoplasms; squamous carcinoma cells from oral
rinses; lung carcinoma cells from bronchial washings; colorectal carcinoma cells from colonic luminal
washings; bladder carcinoma cells from urine or bladder washings; and breast carcinoma or thyroid cancer
cells from fine needle aspirations. Such clinical tests for telomerase can be useful as non-invasive and cost-
effective methods for early detection and monitoring of cancer. In addition, telomerase activity has been
shown to correlate with poor clinical outcome in late-stage diseases such as non-small cell lung cancer,
colorectal cancer, and soft tissue sarcomas. In such cases, testing for telomerase activity can be used to
identify patients with a poor prognosis and to select those who might benefit from adjuvant treatment.
Our review of the latest medical advances in this field reveals that telomerase holds great promise as a 
biomarker for early cancer detection and monitoring, and has considerable potential as the basis for 
developing new anticancer therapies.
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Telomeres are protective caps that function to
contain unique hexameric repeats (TTAGGG)n at
the ends of chromosomes, thought to be essen-
tial regulators of cell life span and chromosomal
integrity.1 Lagging strand DNA synthesis at the
very end of chromosomes cannot be completed,
which results in the progressive shortening of
telomeric repeats with each round of division. This
phenomenon is the so-called “end-replication
problem”.2 Once telomeres have shortened to a
critical length, cells undergo replicative senescence.
For unlimited proliferation and genomic stability,
cells need to compensate for the end-replication
problem by using one of two known telomere-
maintenance mechanisms: telomerase activation
or alternative lengthening of telomeres.
Telomerase is a ribonucleoprotein enzyme
complex that synthesizes telomeric repeats at the
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chromosomal ends. Telomerase has two essential
components: an RNA subunit, called hTR (telo-
merase RNA),3 which contains a template sequence
on which the telomeric repeats are synthesized;
and a protein, human telomerase reverse transcrip-
tase (hTERT), which shows structural and func-
tional similarities to viral reverse transcriptases.4
There are currently a number of methods used
to detect telomerase activity. The telomeric repeat
amplification protocol assay (TRAP), a method
based upon a polymerase chain reaction (PCR),
has been available since 1994, and has become
the standard method for studying the diagnostic
relevance of this enzyme.1 Telomerase activity
has also been specified qualitatively and quanti-
tatively using modified TRAP assays; examples
include TRAP–enzyme linked immunosorbent
assay, the fluorescent TRAP assay, and the TRAP
hybridization assay. Other methods have focused
on the detection of the telomerase subunits, hTR
and hTERT, using the reverse transcriptase PCR
(RT-PCR) method. Real-time PCR methods have
made possible the quantitative and reproducible
determination of hTR and hTERT, whereas expres-
sion of the hTERT protein has been analyzed by
immunocytochemistry using anti-hTERT mono-
clonal or polyclonal antibodies.
Telomere maintenance is regarded as an im-
portant mechanism by which tumor cells evade
senescence, and in most cases, it is achieved by
reactivating or upregulating telomerase activity.
In fact, by using the highly sensitive methods
mentioned above, various human cancers have
been analyzed and a strong correlation has been
shown to exist, both in vitro and in vivo, between
telomerase activity and tumor malignancy. Kim
et al1 have demonstrated that telomerase activity
can be detected in various solid tumors and in
hematological malignancies. Furthermore, work
in many laboratories worldwide has shown that
telomerase is active in 80–90% of human cancers.5
Although most normal somatic tissue lacks de-
tectable telomerase activity, increasingly, the study-
based analysis of primary human samples has
revealed modest levels of telomerase activity in pro-
liferative tissues with high renewal potential: for
example, bone marrow, tissue from the gastroin-
testinal tract and uterine endometrium, and acti-
vated lymphocytes. Within these renewing tissues,
telomerase is most active in the resident stem/
progenitor cell compartments–particularly in
early hematopoietic progenitor cells and in the
gastrointestinal crypt epithelium.
Detecting Telomerase/hTERT in Clinical
Samples of Human Malignant Tumors
During the process of carcinogenesis, telomerase
is activated at different stages. In some instances,
telomerase can be activated gradually through-
out the progression of the cancer, whereas in
other cases, this enzyme might already be ubiq-
uitously expressed at the in situ or precancerous
stage. These differences might affect the clinical
utility of telomerase as a diagnostic marker or
prognostic index. Early studies of telomerase ac-
tivity in cancerous tissue were marked by the use
of different approaches; different objectives were
stipulated and several methods, both qualitative
and quantitative, were used. Initially, most studies
aimed at analyzing telomerase activity in cancer-
ous bodies and the surrounding macroscopically
healthy tissue. Later, the main objective of these
studies was to verify whether telomerase activity
could offer a reliable and non-invasive diagnos-
tic or prognostic tool. More recent studies have
focused on targeting telomerase as a novel form
of cancer therapy.
One problem for the TRAP assay is that it is a
solution-phase technique, thus, information about
the cell type that expresses the telomerase is lost.
Cancer cells, as well as some cells from healthy
tissue and benign lesions (including germ cells,
lymphocytes, stem or its progenitor cells, and
certain epithelial cells) exhibit telomerase activ-
ity; therefore, it is not possible to know whether
telomerase activity is coming from the tumor cells
in the sample. To overcome this limitation, an 
in situ TRAP assay, which uses fluorescent dyes and
microscopy to visualize telomerase activity in the
nuclei of cells of interest, is needed to determine
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whether telomerase expression is derived from
normal telomerase-positive cells or from malig-
nant cells. Another solution is to use quantitative
TRAP or real-time PCR methods to define thresh-
old values that can help distinguish cancer from
normal tissue.
Telomerase is activated in 80–90% of human
cancers. Telomerase expression is not usually de-
tectable in somatic cells; therefore, its detection
holds promise as a diagnostic tool for many
types of carcinoma. In addition, telomerase is also 
activated in some premalignant tissue; thus, it is
reasonable for physicians to expect that testing
for telomerase activity is a useful method for the
screening of high-risk patients. Hence, it is cru-
cial to determine which cancers possess early ro-
bust telomerase activity and which manifest little to
no telomerase activity, even in the most advanced
stages of malignancy.
Expression of the hTR subunit has been found
in all cells, regardless of the presence or absence of
telomerase expression, although it is often am-
plified in cancer cells. However, hTERT expression
correlates with telomerase activity because its
presence is essential for enzymatic activity. Thus,
detection of the hTERT mRNA is considered to be
a more reliable marker of the presence of cancer
cells in clinical samples. Our present article reviews
the role of telomerase activation and its conse-
quences with respect to clinical characteristics in
relation to several types of human cancer. We also
discuss the use of human telomerase and hTERT
expression as diagnostic markers for the early 
detection of human cancer and/or as prognostic
tools for predicting individual patient outcomes.
Breast
Normal mammary tissue does not exhibit de-
tectable telomerase activity. In contrast, telomerase
activity/hTERT expression has been detected in
75–90% of ductal carcinoma in situ lesions and in
90% of invasive breast cancers.6–11 Yashima et al12
have detected a link between a progressive in-
crease in mean telomerase levels and an increase
in the severity of histopathological change: a cor-
relation of 14% in benign breast diseases, 92%
in ductal carcinoma in situ, and 94% in invasive
breast cancers. Although Sugino et al7 and Nawaz
et al13 have found that there is no correlation be-
tween telomerase activity and tumor size or the
occurrence of lymph node metastasis, Clark et al14
have reported that telomerase activity is associ-
ated with a more aggressive tumor phenotype in
patients with node-positive breast cancer. Recently,
hTERT mRNA levels have been reported to be
higher in patients who have recurrent disease or
who have died from breast cancer, which suggests
that the level of hTERT expression can be used as
a prognostic marker.15 (Table 1)
Fine-needle aspiration (FNA) biopsy of breast
tissue is a minimally invasive sampling proce-
dure with a proven value for achieving an initial
Table 1. Breast
Tissue
Positive ratio for telomerase activity % (positive/total number)
Reference
Normal/adjacent tissue Benign/premalignant lesion Malignant lesion
Breast cancer 4 (2/55) 45 (9/20) 93 (130/140) [8]
0 (0/6) 7 (1/15) 73 (52/71) [7]
0 (0/10) 20 (1/5) 95 (99/104) [6]
0 (0/13) 11 (1/9) 79 (22/28) [13]
75 (101/134) [11]a
FNA of breast 10 (3/29) 67 (10/15) [7]
56 (9/16) 90 (17/19) [19]
6 (5/85) 92 (80/87) [16]
aDetection of hTERT. FNA= fine-needle aspiration.
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evaluation of patients with palpable breast lesions.
Many efforts have been made to assess the added
value of testing for telomerase activity for the inter-
pretation of breast FNA samples.16 Approximately
10–40% of fibroadenoma tissue samples display
low-level telomerase activity and hTERT expres-
sion, therefore, screening of FNA samples for
telomerase/hTERT expression (with careful at-
tention to benign diseases) is likely to become a
powerful tool for the detection of breast cancer.
However, even though the expression of telo-
merase in a highly suspicious breast FNA biopsy
sample can upgrade the diagnosis to malignancy, 
a negative test result for telomerase cannot exclude
the possibility of carcinoma.17–19
Lung
Telomerase activity has been demonstrated in
small cell lung cancer (SCLC) and non-small cell
lung cancer (NSCLC), including squamous cell
carcinoma, adenocarcinoma, large cell carcinoma,
as well as pulmonary sarcoma and mesothe-
lioma.20–27 The vast majority of NSCLCs display
substantial telomerase activity: 62–94% of cases
test positive (except for bronchioloalveolar carci-
noma, which is telomerase positive in <50% of
cases).22 SCLC is telomerase positive in 90–100%
of cases, and expresses very high levels of enzyme
activity. For NSCLC and SCLC, the presence of
telomerase activity is correlated with poor survival,
histological type, grade and smoking status.23,28,29
Several studies using NSCLC tissue samples
have also reported that hTERT mRNA and hTERT
protein are overexpressed in lung cancer biopsies
when compared with normal lung tissue. However,
the prognostic significance of hTERT expression or
activity in NSCLC remains controversial. Although
most studies have associated overexpression with
poor prognosis,28,30–33 others have failed to de-
monstrate any prognostic impact for this factor
in NSCLC.23,34,35 For example, Marchetti et al28
have shown that, in stage I NSCLC patients, the
hTERT expression levels are strongly correlated
with reduced probability of survival. On the other
hand, Lu et al35 have not found a prognostic sig-
nificance for hTERT mRNA expression in resected
stage I NSCLC patients when performing a multi-
variate analysis of six molecular markers. However,
Metzger et al36 have recently demonstrated a sur-
vival benefit for patients with NSCLC who have
high hTERT mRNA expression.
High levels of telomerase activity have been
observed in specimens obtained by bronchoalve-
olar lavage, by bronchial washing, and by brushing
tissue samples acquired during bronchofibros-
copy.37–41 The sensitivity and specificity of these
tests for telomerase activity are 70–80% and 80–
90%, respectively. Thus, the use of a cell-extract-
based or an in situ TRAP assay, as complements to
a cytological examination, might make the diag-
nosis of lung cancer more reliable.
Measurement of telomerase activity in sputum
is a non-invasive method for the detection of
lung cancer. However, in view of the lower-than-
desired sensitivity of this test, sputum telomerase
detection can be usefully combined with other
biomarkers for early detection of lung cancer.40,42
For lung cancer that produces pleural effu-
sion, testing for telomerase activity in these effu-
sions has been shown to be a more sensitive tool
than conventional cytology for the detection of
malignant cells.43–45 Positive telomerase activity
suggests a more aggressive tumor and poorer
prognosis. Moreover, telomerase activity could
be a useful adjunct to cytological methods in the
diagnosis of pleural micro-metastasis in patients
with NSCLC. However, several groups have found
telomerase activity is often observed in tubercu-
lous pleural effusions.46,47 That is, false-positive
telomerase activity due to lymphocytic contami-
nation might weaken the diagnostic value of
telomerase activity in parts of the world where
tuberculosis in endemic. (Table 2)
Digestive Organs: Stomach and Colon
Stomach
Although expression of telomerase activity and
hTERT is generally more abundant in gastric cancer
Telomerase activity in human cancer
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samples than in corresponding normal mucosa,
there exists a significant overlap.48–55 Consequently,
the clinicopathological significance of telomerase
activity in gastric cancer is controversial. Some
studies have indicated that telomerase activity in
gastric tumor tissue correlates well with tumor
differentiation and depth of invasion,56,57 whereas
several other studies have shown no correlation
between clinical or histological factors and telo-
merase activity.50,52,54
Telomerase activity in gastric lavage fluid is a
sensitive potential tumor marker that might help
increase the gastric cancer detection rate when
combined with conventional cytopathological
methods.58 Telomerase expression has also been
found in the peritoneal fluid of patients with
gastric cancer.59–61 In these studies, the presence
of telomerase activity is associated with advanced
stages of the disease or peritoneal metastasis.
Colon
The progression from normal or inflamed epithe-
lium to the final stage of colorectal cancer involves
morphological changes to precancerous dyspla-
sia and adenomatous polyps. Many studies have
revealed a detectable level of telomerase activity
in normal mucosa.62,63 In adenomatous polyps,
telomerase activity is frequently present and is
apparently connected to dysplasia grade and
polyp size.64 That is, although telomerase activity
is overexpressed in colorectal carcinoma,65–67 it
cannot be used as a marker to screen patients with
this malignancy. However, a high level of hTERT
mRNA is associated with advanced stages, includ-
ing metastatic colon carcinoma.68
Colorectal carcinoma is suggested as a serious
sequela of inflammatory bowel diseases such as
ulcerative colitis. However, Usselmann et al69 have
observed that, in all regions of the colon, when
Table 2. Lung
Tissue
Positive ratio for telomerase activity % (positive/total number)
Reference
Normal/adjacent tissue Benign/premalignant lesion Malignant lesion
NSCLC 4 (3/68) 78 (98/125) [20]
85 (84/99) [21]
0 (0/107) 62 (66/107) [22]
0 (0/115) 93 (107/115) [23]
0 (14/14) 71 (56/79) [27]
0 (0/14) 90 (62/69) [36]b
0 (0/115) 94 (108/115) [23]b
SCLC 100 (11/11) [20]
93 (14/15) [24]
Malignant pleural 8 (5/63) 83 (5/6) [46]
effusion of 
lung cancera
0 (0/32) 100 (11/11) [45]
Bronchial wash 82 (18/22) [38]
or lavage
29 (6/21) 78 (29/37) [37]
8 (1/13) 70 (16/23) [39]
10 (1/10) 68 (26/42) [40]
14 (1/7) 73 (16/22) [41]
Sputum 0 (0/10) 82 (31/42) [40]
10 (3/30) 68 (23/34) [42]
aMalignant pleural fluid has diagnosed by cytology; bDetection of hTERT. FNA= fine-needle aspiration; NSCLC=non-small cell lung
cancer; SCLC= small cell lung cancer.
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compared to samples from normal individuals,
there is a significantly reduced presence of telo-
merase activity in biopsies from patients with 
ulcerative colitis.
Telomerase activity and hTERT have been de-
tected in small tissue samples from patients with
colorectal carcinoma, including samples such as
exfoliated cancer cells from colonic washings and
colonic brush specimens.62,63,70,71 The specificity
of these tests is remarkable, but their sensitivity
is relatively low. (Table 3)
Urinary Organs: Kidney and Bladder
Kidney
Telomerase activity is expressed in renal cell 
carcinoma less frequently than in other malig-
nancies.72–79 Furthermore, even when telomerase
activity is found to be activated in renal tumor
tissue, its expression is not related to clinicopatho-
logical parameters (histopathological grade, DNA
ploidy, tumor stage, and clinical outcome).72,73,78,80
That is, telomerase activity could be a potential
marker for malignancy, but it is not suitable as a
prognostic marker for renal cell carcinoma.
Bladder
Telomerase activity and hTERT are detected in
about 90% of bladder cancers.81–86 However,
their presence is not specific to malignancy. 
A variable percentage of normal tissue from
tumor-adjacent zones or from non-cancerous
samples tests positive for telomerase. Some stud-
ies have found that the presence of telomerase
activity or increased hTERT expression is associ-
ated with pathological grade and clinical stage of
cancer.81,86
Table 3. Stomach and colon
Tissue
Positive ratio for telomerase activity % (positive/total number)
Reference
Normal/adjacent tissue Benign/premalignant lesion Malignant lesion
Gastric cancer 85 (56/66) [48]
0 (0/20) 27 (4/15) 85 (17/20) [49]
89 (85/95) [50]
8 (1/12) 70 (7/10) [51]
0 (0/30) 38 (11/29) 93 (27/25) [52]
95 (41/43) 98 (42/43) [54]
62 (23/37) 90 (33/37) [55]b
Stomach lavage 0 (0/20) 28 (7/25) 80 (20/25) [58]
Peritoneal washingsa 50 (10/20) [59]
63 (20/32) [60]
100 (13/13) [61]
Colorectal cancer 0 (0/50) 53 (16/30) 90 (45/50) [65]
14 (5/35) 50 (6/12) 92 (32/35) [62]
27 (3/11) 67 (14/21) 97 (33/34) [63]
0 (0/100) 96 (96/100) [66]
80 (98/122) [67]
45 (5/11) 57 (12/21) 94 (32/34) [63]b
Colon biopsy 0 (0/30) 50 (6/12) 88.5 (46/52) [70]
Colon washing 0 (0/9) 60 (9/15) [62]
0 (0/11) 58 (11/19) [71]
0 (0/11) 0 (0/21) 62 (21/34) [63]
aClinically evident peritoneal metastases; bdetection of hTERT. ESCC= esophageal squamous cell cancer.
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Testing for telomerase in exfoliated cells col-
lected from urine or bladder washings seems a
promising tool for the diagnosis and manage-
ment of bladder cancer.82,83,87–96 Urine samples
can be collected easily, therefore, the ability to
detect telomerase activity in urine samples could
make telomerase a convenient diagnostic marker
for this tumor. In fact, previous studies have shown
that an assay of telomerase activity performed on
voided urine is an important non-invasive tool
for the diagnosis of bladder tumors, because this
test has high sensitivity (46–92%) and speci-
ficity (66–95%) for even early-stage and low-grade
tumors.82,83,89–95 However, results from differ-
ent studies have suggested that telomerase activ-
ity in urine is not related to tumor grade, size, 
or stage. The main limitation of this test is the
rate of false-positive results due to the presence
of inflammatory or non-tumor cells (i.e. epi-
thelial cells from the lower genital tract), which
can express telomerase activity.87 As an alter-
native, the assessment of hTERT expression in
urine represents a more sensitive and specific 
test for the detection of primary urothelial neo-
plasms than do tests for telomerase activity.88,95,97
(Table 4)
Table 4. Kidney and bladder
Tissue
Positive ratio for telomerase activity % (positive/total number)
Reference
Normal/adjacent tissue Benign/premalignant lesion Malignant lesion
RCC 0 (0/56) 71 (40/56) [72]
17 (6/35) 74 (26/35) [73]
0 (0/21) 56 (28/50) [74]
0 (0/26) 82 (23/28) [75]
0 (0/52) 0 (0/8) 64 (28/44) [76]
0 (0/11) 17 (1/6) 60 (32/53) [77]
0 (0/30) 60 (18/30) [78]
16 (5/32) 86 (31/36) [75]a
75 (15/20) 90 (18/20) [79]a
Bladder cancer 0 (0/7) 50 (1/2) 98 (39/40) [81]
0 (0/17) 86 (48/56) [82]
0 (0/37) 98 (41/42) [83]
0 (0/10) 0 (0/10) 100 (26/26) [84]
29 (4/14) 50 (2/4) 79 (11/14) [85]
0 (0/6) 100 (35/35) [86]a
Bladder washing 0 (0/12) 84 (36/43) [83]
4 (1/23) 96 (22/23) [89]
2 (2/86) 75 (62/82) [96]a
Urine 4 (3/83) 62 (16/26) [82]
0 (0/35) 34 (16/47) 85 (88/104) [87]
18 (9/50) 78 (42/54) [90]
9 (7/80) 46 (32/70) [91]
8 (6/79) 93 (112/121) [92]
12 (10/84) 90 (121/134) [93]
34 (49/144) 87 (59/68) [94]
0 (0/30) 24 (20/85) 75 (150/200) [95]
4 (1/26) 80 (26/33) [97]a
0 (0/51) 5 (4/77) 92 (134/146) [88]a
0 (0/30) 12 (10/85) 96 (192/200) [95]a
aDetection of hTERT. RCC= renal cell cancer.
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Female Genital Organs: Uterus and Ovary
Uterus
Telomerase activity is found in almost all cancer
tissue samples, as well as in most normal epi-
thelial tissues samples from the uterus and the
fallopian tubes of reproductive-age women.98–100
With regard to the endometrium, telomerase ac-
tivity is high during the proliferative phase of the
menstrual cycle but suppressed during the secre-
tory phase. Moreover, telomerase activity is rarely
detected in postmenopausal women. These find-
ings reflect the relationship between telomerase
activity and features of the normal endometrium,
which is regularly regenerated and has high prolif-
erative activity. Thus, although telomerase activity
is frequently detected in endometrial malignan-
cies, a high frequency of telomerase positivity
(up to 90%) has also been found in proliferative-
phase endometrium.99,101–104 The detection of
telomerase in endometrial cancer is often not as-
sociated with architectural grade, myometrial in-
vasion, or stage. However, although the presence
of telomerase activity in the endometrium pres-
ents some difficulties for achieving a diagnosis
and prognosis for cancer, the quantitative analy-
sis of hTERT can have a role as a diagnostic or
prognostic adjunct for patients with endometrial
cancer.105
Cervical cancer evolves from pre-existing non-
invasive premalignant lesions referred to as cervi-
cal intraepithelial neoplasia (CIN), graded CIN1 to
CIN3. Elevated hTERT mRNA levels and telo-
merase activity can be detected in a marked subset
of CIN3 lesions and >90% of cervical carcinomas,
whereas normal cervical tissue and low-grade CIN
lesions only rarely show increased hTERT levels
and telomerase activity.98,103,106–111 According to a
study by Kruse et al,112 telomerase is not a prog-
nostic marker in early CIN, because telomerase
activity reflects a rather late step in the sequence
from CIN3 to squamous cervical cancer. However,
a connection between increasing hTERT expres-
sion and a trend toward greater severity of cervi-
cal lesions has been found by Tsezou et al113 and
Wisman et al.114 In addition, Wang et al115 have
reported that the frequency of hTERT mRNA is
related to the grade of CIN and cervical cancer.
Gestational trophoblastic disease refers to a
category of neoplasm that includes complete hy-
datidiform mole, partial hydatidiform mole, and
choriocarcinoma. All of these tumors are preg-
nancy-related and have proliferative neoplastic
trophoblasts. Previously, we have found that telo-
merase activity is at its highest level during the
early period of normal pregnancy and decreases
significantly after the first trimester.116 In addi-
tion, we have found that telomerase activity oc-
curs in a similar fashion in placental tissue from
normal early pregnancy and neoplastic tropho-
blastic tissue. Cheung et al117 also have found
that telomerase activity is present in choriocarci-
noma as well as in early placental tissue and hy-
datidiform moles. The presence of telomerase
activity in complete hydatidiform moles is also
associated with the development of persistent
gestational trophoblastic tumors (such as invasive
moles and choriocarcinoma).117,118 That is, prolif-
erative normal and neoplastic trophoblasts possess
similar levels of telomerase activity. However, there
is a significant difference between the two: in
normal pregnancy, telomerase activity is down-
regulated over the course of gestation, whereas in
hydatidiform mole, it is not.
Ovaries
Epithelial neoplasms of the ovary aggregate into
three distinct clinicopathological groups: benign
neoplasms confined to the ovary, cytologically
malignant cancerous neoplasms, and an inter-
mediate group referred to as borderline tumors
or low-malignant-potential (LMP) tumors. The
LMP tumors show significantly less aggressive
behavior than classic epithelial ovarian carcino-
mas. Previous studies have reported telomerase
activity in normal ovarian tissue and tumors, with
the majority of frank ovarian carcinomas express-
ing telomerase activity.99,103,119–124 However, stud-
ies of the rate of telomerase activity in benign
and LMP ovarian tumors have produced mixed
results. Wan et al120 have reported that, although
the majority of cystadenomas do not express
Telomerase activity in human cancer
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telomerase, all LMP tumors do express this en-
zyme. Oishi et al125 have found that only 60% 
of LMP tumors are telomerase positive, whereas
Yokoyama et al99 have found that 40% of ovarian
cystadenomas express telomerase activity. Thus,
the detection of telomerase activity might be 
useful as an affiliated diagnostic procedure to
help discriminate between malignant and be-
nign tissue, but it should not be used in for
pathological diagnosis.126 However, hTERT expres-
sion might be a useful marker of patient response
to platinum-based therapy during advanced stages
of ovarian cancer.126 (Table 5)
Sarcoma
Sarcoma cells have a relatively low level of telo-
merase expression compared to carcinoma cells.
In fact, several types of sarcoma more commonly
express alternative lengthening of telomeres 
and exhibit a markedly elongated telomere
Table 5. Uterus and ovary
Tissue
Positive ratio for telomerase activity % (positive/total number)
Reference
Normal/adjacent tissue Benign/premalignant lesion Malignant lesion
Endometrial cancer 63 (5/8) 100 (6/6) [103]
89 (39/44) 100 (28/28) [99]
88 (15/17) [102]
100 (14/14) 95 (19/20) [104]
11 (1/9) 97 (35/36) [100]a
Cervical cancer 71 (5/7) 83 (10/12) [98]
0 (0/5) 100 (6/6) [103]
0 (0/5) 100 (16/16) [106]
0 (0/35) 29 (6/21) 92 (22/24) [107]
19 (3/16) 48 (29/61) 91 (21/23) [108]
7 (2/27) 92 (42/50) [109]
0 (0/8) 79 (85/107) [110]
13 (1/8) 80 (83/104) [110]a
0 (0/20) 67 (29/43) 90 (36/40) [111]a
Cervical smear for 0 (0/10) 5 (1/22) 50 (1/2) [103]
cervical cancer 0 (0/43) 69 (11/16) 97 (28/29) [136]
13 (7/88) 93 (51/55) 100 (59/59) [137]a
GTD 48 (53/111) 83 (15/18) 100 (3/3) [116]
34 (12/35) 31 (11/35) 100 (1/1) [117]
0 (0/4) 52 (16/31) 100 (5/5) [118]
Ovarian cancer 0 (0/5) 92 (12/13) [103]
20 (2/10) 77 (24/31) [119]
21 (5/24) 100 (37/37) [120]
30 (3/10) 40 (6/15) 96 (24/25) [99]
33 (2/6) 31 (4/13) 74 (69/93) [121]
27 (3/11) 85 (22/26) [122]
36 (4/11) 88 (22/25) [122]a
0 (0/12) 4 (1/28) 61 (20/33) [123]a
Peritoneal washings 5 (2/43) 64 (27/42) [124]
of ovarian cancer
aDetection of hTERT. GTD=gestational trophoblastic disease.
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length.127–129 The positive ratios of detectable
telomerase are 10–86% in malignant soft-tissue
tumors129–133 and 11–58% in malignant bone
tumors.128,134,135 For example, the rate of telo-
merase expression in liposarcoma, malignant 
histiocytoma and chondrosarcoma samples is
26–86%, 22–80% and 11–44%, respectively. That
is, according to different reports, the frequency of
telomerase activity varies greatly among different
sarcoma subtypes, which could be due to the 
homogeneous characteristics of sarcomas. Finally,
although the expression of telomerase differs be-
tween sarcoma subtypes, some studies have re-
ported that telomerase activity correlates with
grade of malignancy.130,132 (Table 6)
Conclusion
Telomerase activity has been measured in a wide
variety of cancerous and non-cancerous tissues,
and the vast majority of clinical studies have
shown a direct association between telomerase
activity and the presence of cancerous cells.
Except for brain tumors, sarcomas, and some epi-
thelial cancers, telomerase shows great promise
as a biomarker for early cancer detection. In ad-
dition, telomerase activity has been shown to
correlate with poor clinical outcome in late-stage
NSCLC,23,28,29 colorectal cancer,68 and soft tissue
sarcomas.130,132 In such cases, testing for telo-
merase activity could be used to identify patients
with poor prognosis and to select those who
might benefit from adjuvant treatment. However,
such testing is associated with several potential
limitations and problems.
Measurable levels of telomerase have also been
detected in carcinoma cells from various cytologi-
cal samples: squamous carcinoma cells in oral
rinses; lung carcinoma cells in bronchial wash-
ings; colorectal carcinoma cells in colonic luminal
washings; bladder carcinoma cells in urine or
bladder washings; and breast carcinoma and thy-
roid cancer cells in FNA biopsies. Such clinical
tests for telomerase could be used as non-invasive
and cost-effective methods for early detection and
Table 6. Sarcoma
Tissue
Positive ratio for telomerase activity % (positive/total number)
Reference
Normal/adjacent tissue Benign/premalignant lesion Malignant lesion
Liposarcoma 0 (0/4) 50 (6/12) [130]
0 (0/2) 86 (12/14) [131]
0 (0/11) 29 (4/14) [132]
63 (12/19) [133]
26 (9/34) [129]
Malignant histiocytoma 22 (2/9) [130]
0 (0/2) 80 (8/10) [131]
67 (6/9) [132]
Leiomyosarcoma 10 (1/10) [130]
Rhabdomyosarcoma 50 (1/2) [130]
Osteosarcoma 44 (31/71) [128]
23 (3/13) 58 (11/19) [134]
11 (1/9) [135]
Chondrosarcoma 43 (3/7) [134]
Ewing’s sarcoma 43 (3/7) [134]
13 (1/8) [135]
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monitoring of cancer. However, large cohort stud-
ies are required to statistically validate the associa-
tion between these markers and cancer.
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